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The molecular epidemiology and mechanisms of resistance of carbapenem-resistant Acinetobacter baumannii (CRAB) were de-
termined in hospitals in the states of the Cooperation Council for the Arab States of the Gulf (Gulf Cooperation Council [GCC]),
namely, Saudi Arabia, United Arab Emirates, Oman, Qatar, Bahrain, and Kuwait. Isolates were subjected to PCR-based detec-
tion of antibiotic resistance genes and repetitive sequence-based PCR (rep-PCR) assessments of clonality. Selected isolates were
subjected to multilocus sequence typing (MLST). We investigated 117 isolates resistant to carbapenem antibiotics (either imi-
penem or meropenem). All isolates were positive for OXA-51. The most common carbapenemases were the OXA-23-type, found
in 107 isolates, followed by OXA-40-type (OXA-24-type), found in 5 isolates; 3 isolates carried the ISAba1 element upstream of
blaOXA-51-type. No OXA-58-type, NDM-type, VIM-type, or IMP-type producers were detected. Multiple clones were detected with
16 clusters of clonally related CRAB. Some clusters involved hospitals in different states. MLST analysis of 15 representative iso-
lates from different clusters identified seven different sequence types (ST195, ST208, ST229, ST436, ST450, ST452, and ST499), as
well as three novel STs. The vast majority (84%) of the isolates in this study were associated with health care exposure. Aware-
ness of multidrug-resistant organisms in GCC states has important implications for optimizing infection control practices; es-
tablishing antimicrobial stewardship programs within hospital, community, and agricultural settings; and emphasizing the need
for establishing regional active surveillance systems. This will help to control the spread of CRAB in theMiddle East and in hos-
pitals accommodating transferred patients from this region.
Acinetobacter baumannii is a major pathogen associated glob-ally with hospital-acquired infections (HAIs). It was found
that 26.5% of ventilator-associated pneumonias in Riyadh, Saudi
Arabia, between 2005 and 2009 were caused by Acinetobacter spp.
(1). The success of this pathogen is partially due to the high prev-
alence of a multidrug-resistant phenotype that A. baumannii now
demonstrates (2). In the Middle East, particularly in states of the
Cooperation Council for the Arab States of the Gulf (Gulf Coop-
eration Council [GCC]; i.e., Saudi Arabia, United Arab Emirates,
Oman, Kuwait, Qatar, and Bahrain), the prevalence of carbap-
enem-resistant A. baumannii (CRAB) has increased dramatically
over the last decade (3). This high prevalence limits treatment
options, which can lead to increased morbidity and mortality due
to infections caused by CRAB.
The phenotypic resistance characteristics of CRAB are mainly
due to the expression of class D carbapenemases, called oxacilli-
nases. Moreover, plasmid-mediated metallo--lactamases (MBL)
have been associated with the resistance phenotype (2). The exis-
tence of ISAba1 elements upstream of the blaOXA-51-type gene is
also associated with the carbapenem resistance phenotype in A.
baumannii by overexpressing the intrinsic OXA-51 carbapen-
emase (4). Previous reports on isolates from the GCC states show
that the carbapenem resistance phenotype in A. baumannii is of-
ten due to the expression of OXA enzymes, particularly OXA-23
(3). However, MBL-encoding genes, including the recently
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emerged New Delhi metallo--lactamase (NDM), have been in-
creasingly reported in Acinetobacter spp. isolated from different
parts of the world (5–7).
Due to the geographic location of the GCC states and the eth-
nic relationships of residents, heavy travel occurs between the
GCC states and the Indian subcontinent, where NDM enzymes
are widespread. The current socioeconomic structure of the GCC
states relies heavily on an international workforce. For example,
about 37% of the total population of the GCC states are non-
national expatriates, mainly from the Indian subcontinent (8).
Saudi Arabia receives more than 1.5 million international pilgrims
from all over the world to perform Hajj (9). This exemplifies the
heavy travel occurring in the GCC region, and travel is known to
be a risk factor for spreading/acquiring antimicrobial-resistant
bacteria (3).
As one of many desperately needed first steps to control the
spread of CRAB, we aimed to determine the molecular genetics of
CRAB in the GCC states. To our knowledge, no region-wide study
on the molecular genetics of CRAB has been undertaken. For this
reason, we have performed a “snapshot” analysis of the molecular
epidemiology of CRAB in the states of the Gulf Cooperation
Council.
MATERIALS AND METHODS
Bacterial isolates.Between July 2011 and January 2013,Acinetobacter spp.
were collected from seven participating institutes across the GCC states
(two hospitals in Saudi Arabia from Riyadh and Khobar and one hospital
each from United Arab Emirates [UAE], Kuwait, Qatar, Oman, and Bah-
rain) (Table 1). These hospitals are part of a region-wide collaborative
study on multidrug-resistant Gram-negative bacilli (10). Acinetobacter
spp. were identified and tested for their susceptibility to a panel of anti-
microbials using semiautomated systems in each clinical microbiology
laboratory (Table 1). Isolates were included on the basis of showing de-
creased susceptibility to imipenem (MIC, 8 g/ml) or meropenem
(MIC, 8 g/ml) using CLSI breakpoints. Only one isolate per patient
was included, and isolates originated from a range of clinical specimens.
Isolates were sent to the research laboratory at the University of
Queensland Centre for Clinical Research (UQCCR).
Antibiotic susceptibility testing.All isolates underwent disk diffusion
susceptibility testing following the methodology and the updated break-
point defined by the European Committee on Antimicrobial Susceptibil-
ity Testing (EUCAST) (11) for the following antimicrobial agents: imi-
penem (10 g), meropenem (10 g), gentamicin (10 g), amikacin (30
g), ciprofloxacin (5 g), and sulfamethoxazole-trimethoprim (23.75
/1.25 g). The updated breakpoints defined by the Clinical and Labora-
tory Standards Institute (CLSI) (12) were also used to assess disk diffusion
susceptibility for ceftazidime (30 g), tetracycline (30 g), ticarcillin-
clavulanic acid (75/10 g), piperacillin-tazobactam (100/10 g), and
ampicillin-sulbactam (10/10 g), since these antibiotics do not have
EUCAST breakpoints available for Acinetobacter spp.
PCR for carbapenemase genes. Genomic DNA was extracted using
the UltraClean microbial DNA isolation kit (Mo Bio Laboratories) as
recommended by the manufacturer. Species identification was performed
using gyrB multiplex PCR as previously described (13). Detection of the
intrinsic carbapenemase-encoding gene blaOXA-51-type was performed us-
ing standard PCR based on the primers listed in Table 2 (14). The samples
were also screened for the other major groups that confer clinically rele-
vant resistance to carbapenems, i.e., blaOXA-23-type, blaOXA-40-type (24-type),
blaOXA-58-type (14, 15), as well as for the blaNDM-type, blaIMP-type, and
blaKPC-type in a multiplex reaction (16, 17) and for blaVIM-type in a single
PCR (18) (Table 2). Isolates not carrying another carbapenemase gene
apart from blaOXA-51-type were subjected to PCR screening for the ISAba1
element upstream of blaOXA-51-type (19) and class 1 integron (intI1) as
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previously described (20) (Table 2). PCRs were carried out using GoTaq
green master mix (Promega, USA).
Clonal analysis of carbapenem-resistant A. baumannii. Genetic re-
latedness among CRAB isolates from the GCC states was determined by
rep-PCR– based typing using the DiversiLab system (bioMérieux, Oak-
leigh, Australia). DNA fragment patterns were analyzed using the Kull-
back-Leibler statistical method to determine clonal relationships and to
create the dendrogram with a 95% cutoff. Isolates were considered related
and defined as rep-PCR clusters if they were95% similar (21, 22).
Representative isolates, determined by DiversiLab rep-PCR clusters,
from the six states were also analyzed by multilocus sequence typing
(MLST). Genotyping by MLST was performed as previously described
(23), using the seven housekeeping genes gltA, gyrB, gdhB, recA, cpn60, gpi,
and rpoD. Analyses of the allele sequences and ST were performed
through the A. baumannii MLST website (http://pubmlst.org
/abaumannii).
Clinical data collection. Clinical data included in this study for each
patient identified as infected or colonized with CRAB were collected by
the participating institutions. A concise one-page questionnaire was used
to collect demographic data, the clinical source of the isolates, microbiol-
ogy results, antibiotic exposure, travel within the last 6 months, and med-
ical history. Hospital-acquired infections were defined by a positive mi-
crobiology culture from an infection in patients who were hospitalized for
48 h. Patients transferred from another hospital had their hospital stay
duration calculated from the date of the first hospital admission (24).
Hospital-acquired colonization was defined by a positive microbiology
culture of surveillance sampling and not associated with the clinical man-
ifestation of an infection from patients who had been hospitalized for48
h. Health care-associated infections were classified as infections occurring
within 48 h after admission in patients who were hospitalized during the
previous 90 days; who received hemodialysis, intravenous medication, or
home wound care in the 30 days before the infection; or who were resi-
dents of nursing homes or long-term-care facilities. Otherwise, cases were
considered to be community acquired (24).
Human ethics. The University of Queensland granted human ethics
clearance to conduct this project (2011000474). Permission from King
Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Saudi
Arabia, was granted to conduct the regionwide collaborative study on
multidrug-resistant Gram-negative bacilli.
RESULTS
Bacterial isolates and carbapenem susceptibility. A total of 117
nonrepetitive isolates nonsusceptible to imipenem and/or mero-
penem were further assessed. The numbers of CRAB isolates
found in each participating hospital were as follows: Riyadh, Saudi
Arabia, 49; Khobar, Saudi Arabia, 31; Kuwait, 8; United Arab
Emirates, 8; Oman, 5; Qatar, 8; Bahrain, 8 (Table 1). Carbapenem
coresistance to sulfamethoxazole-trimethoprim (93%), gentami-
cin (95%), amikacin (83%), ciprofloxacin (98%), tetracycline
(68%), ticarcillin-clavulanic acid (100%), piperacillin-tazobac-
tam (100%), and ampicillin-sulbactam (74%) was found for the
117 CRAB isolates.
Carbapenemase-encoding genes. All 117 isolates were posi-
tive for blaOXA-51-type. The clinically relevant carbapenemase-en-
coding gene blaOXA-23-type was found in 107 isolates (91%). As a
breakdown, 47 (96%) of the CRAB isolates from Riyadh, Saudi
Arabia, 28 (90%) from Khobar, Saudi Arabia, 3 (38%) from Bah-
rain, and all from Oman (n 5), Kuwait (n 8), Qatar (n 8),
and UAE (n 8) carried blaOXA-23-type. Five isolates from Bahrain
carried blaOXA-40-type genes. None of the isolates had a positive
PCR result for blaOXA-58-type, blaNDM-type, blaKPC-type, blaIMP-type,
or blaVIM-type. Five (4%) of the CRAB isolates did not give positive
PCR results for any of the tested carbapenemase-encoding genes
except blaOXA-51-type. None of these five isolates carried the class 1
integron, but 3 isolates (2.8%) (from Khobar, Saudi Arabia) car-
ried the ISAba1 element upstream of blaOXA-51-type, which is
known to mediate the carbapenem resistance phenotype (4). Two
isolates (1.7%) (from Riyadh, Saudi Arabia) remained negative
for all the tested carbapenemase genes.
Genotyping and clonality. A total of 16 DiversiLab rep-PCR
clusters (clusters A to P) and 11 singletons were identified among
the 117 study isolates (Table 3; see also Fig. S1 in the supplemental
material). The main cluster (B) included 53 of the 117 isolates
(45%) and represented isolates from all six locations (five states).
The rep-PCR analysis showed that 11 isolates had unique banding
TABLE 2 Sequence of primers used to screen for the carbapenemase-encoding genes, ISAba1 upstream of blaOXA-51-type, and class 1 integron
Primer Target Sequence (5= to 3=) Size (bp) Annealing temperature (°C) Reference
OXA-51-F blaOXA-51 TAATGCTTTGATCGGCCTTG 353 60 14
OXA-51-R TGGATTGCACTTCATCTTGG
OXA-23-F blaOXA-23 GATGTGTCATAGTATTCGTCG 1,065 52 15
OXA-23-R TCACAACAACTAAAAGCACTG
OXA-40-F blaOXA-40 (24) GGTTAGTTGGCCCCCTTAAA 246 50 14
OXA-40-R AGTTGAGCGAAAAGGGGATT
OXA-58-F blaOXA-58 AAGTATTGGGGCTTGTGCTG 599 56 14
OXA-58-R CCCCTCTGCGCTCTACATAC
NDM-F blaNDM GCAGGTTGATCTCCTGCTTG 203 55 16
NDM-R ACGGTTTGGCGATCTGGT
IMP-F blaIMP CTACCGCAGCAGAGTCTTTGC 591 58 17
IMP-R GAACAACCAGTTTTGCCTTACC
KPC-F blaKPC ATCTGACAACAGGCATGACG 452 55 16
KPC-R GACGGCCAACACAATAGGTG
VIM-F blaVIM GATGGTGTTTGGTCGCATA 390 55 18
VIM-R CGAATGCGCAGCACCAG
ISAba1-F Upstream CACGAATGCAGAAGTTG 1,107 58 19
OXA-51-R TGGATTGCACTTCATCTTGG
HS317 intI1 GAACCTTGACCGAACGC Variable 50 20
HS320 AGTAAAGCCCTCGCTAG
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patterns. These singletons were unrelated to the remaining iso-
lates, representing various locations, except for singleton 1, which
was only slightly less than 95% similar to cluster A isolates.
Well-defined clusters by location were seen in clusters A, C, F,
H, M, N, and P (Table 3), whereas the remaining rep-PCR clones
included isolates from two or more locations. Isolates harboring
blaOXA-23-type genes were scattered throughout the rep-PCR pat-
terns, except for clusters K, L, and M, in which all of the isolates
carried blaOXA-51-type and blaOXA-23-type genes.
Seven different sequence types (ST195, ST208, ST229, ST436,
ST450, ST452, and ST499) and three novel STs were assigned to
the 15 representative isolates. ST195 isolates clustered with ST208
within the same cluster; note that there is only a single allele dif-
ference between these two sequence types, which represents a true
single locus variant. ST195, ST208, and ST436 fall under the
widely disseminated clonal complex CC92 (also known as inter-
national clone number 2), while ST229 is under CC110 (also
known as international clone number 3). We found good corre-
lation between the sequence types and the rep-PCR clusters.
Clinical data. The clinical data are summarized in Table 4.
Demographic and clinical data were successfully retrieved for 100
patients (85%) as follows: Riyadh, Saudi Arabia, 49; Khobar,
TABLE 3 Clustering results based on rep-PCR patterns of 117 carbapenem-resistant A. baumannii isolates from the GCC statesa
Cluster or singleton
No. of isolates
Sequence typeTotal By location By carbapenemase geneb
Clusters
A 8 Riyadh, Saudi Arabia, 8 blaOXA-51-type and blaOXA-23-type ND
c
B 53 Riyadh, Saudi Arabia, 22 blaOXA-51-type and blaOXA-23-type, 21;
blaOXA-51-type, 1
ST195; clustered with ST195 and ST208d
Khobar Saudi Arabia, 19 blaOXA-51-type and blaOXA-23-type, 18; ISAb1
upstream of blaOXA-51-type, 1
Novel ST; clustered with novel ST and ST208
Kuwait, 6 blaOXA-51-type and blaOXA-23-type ST208; clustered with novel ST and ST195
d
Bahrain, 2 blaOXA-51-type and blaOXA-40-like ST208; clustered with ST208
Oman, 3 blaOXA-51-type and blaOXA-23-type ST195; clustered with ST195
UAE, 1 blaOXA-51-type and blaOXA-23-type Clustered with ST195
C 3 Bahrain, 3 blaOXA-51-type and blaOXA-40-like ND
D 2 Riyadh, Saudi Arabia, 2 blaOXA-51-type and blaOXA-23-type ND
E 3 Riyadh, Saudi Arabia, 2 blaOXA-51-type and blaOXA-23-type, 1; blaOXA-51-type, 1 ST499; clustered with ST499
Kuwait, 1 blaOXA-51-type and blaOXA-23-type Clustered with ST499
F 2 UAE, 2 blaOXA-51-type and blaOXA-23-type ND
G 5 Riyadh, Saudi Arabia, 1 blaOXA-51-type and blaOXA-23-type ST450
Khobar, Saudi Arabia, 3 blaOXA-51-type and blaOXA-23-type Clustered with ST450
UAE, 1 blaOXA-51-type and blaOXA-23-type
H 3 Bahrain, 3 blaOXA-51-type and blaOXA-23-type ST452; clustered with ST452
I 4 Riyadh, Saudi Arabia, 4 blaOXA-51-type and blaOXA-23-type Novel ST; clustered with novel ST
J 3 Riyadh, Saudi Arabia, 3 blaOXA-51-type and blaOXA-23-type ND
K 8 Qatar, 6 blaOXA-51-type and blaOXA-23-type ST299; clustered with ST299
Kuwait, 1 blaOXA-51-type and blaOXA-23-type Clustered with ST299
UAE, 1 blaOXA-51-type and blaOXA-23-type Clustered with ST299
L 2 Qatar, 2 blaOXA-51-type and blaOXA-23-type ST299; clustered with ST299
M 3 Khobar, Saudi Arabia, 3 blaOXA-51-type and blaOXA-23-type Novel ST; clustered with novel ST
N 3 Khobar, Saudi Arabia, 3 blaOXA-51-type and blaOXA-23-type ST436; clustered with ST436
O 2 Oman, 1 blaOXA-51-type and blaOXA-23-type ND
Riyadh, Saudi Arabia, 1 blaOXA-51-type and blaOXA-23-type ND
P 2 Khobar, Saudi Arabia, 2 ISAb1 upstream of blaOXA-51-type ND
Singletons
1 Riyadh, Saudi Arabia blaOXA-51-type and blaOXA-23-type ST195
2 UAE blaOXA-51-type and blaOXA-23-type ND
3 Riyadh, Saudi Arabia blaOXA-51-type and blaOXA-23-type ND
4 UAE blaOXA-51-type and blaOXA-23-type ND
5 Riyadh, Saudi Arabia blaOXA-51-type and blaOXA-23-type ND
6 UAE blaOXA-51-type and blaOXA-23-type ND
7 Khobar, Saudi Arabia blaOXA-51-type and blaOXA-23-type ND
8 Oman blaOXA-51-type and blaOXA-23-type ND
9 Riyadh, Saudi Arabia blaOXA-51-type and blaOXA-23-type ND
10 Riyadh, Saudi Arabia blaOXA-51-type and blaOXA-23-type ND
11 Riyadh, Saudi Arabia blaOXA-51-type and blaOXA-23-type ND
a For a full dendrogram, see Fig. S1 in the supplemental material.
b No number indicates that all isolates were the same type(s).
c ND, not determined.
d There is only a single allele difference between sequence types ST195 and ST208.
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Saudi Arabia, 30; United Arab Emirates, 8; Oman, 5; Bahrain, 8.
We found that 25 of the patients were  70 years old, and the
second group (n 23) was between 18 and 30 years old (Table 4).
Most of the identified patients were male (n 68) and local citi-
zens (n  79). CRAB isolates were mainly isolated from swab
specimens (n  39) and sputum (n  22), and blood (n  18)
samples (Table 4). Note that 24% of the isolates represented health
care-associated infections, while 53% were associated with hospi-
tal-acquired (nosocomial) infections and 7% were colonizing
hospital patients. Eight percent of the isolates were classified as
community acquired, and we did not categorize the last 8% of
isolates due to lack of data. Antibiotics were administered to 87
patients before the isolation of CRAB. Overseas medical treatment
information was not collectable for 50% of the patients. Four pa-
tients had recently traveled to Bangladesh, India, Singapore, or
Thailand for medical proposes. An isolate from a UAE patient
who recently traveled to Bangladesh for medical purposes clus-
tered with another isolate from a UAE patient with no recent
travel (cluster F) (Table 3; see also dendrogram in Fig. S1 of the
supplemental material). Interestingly, a UAE isolate obtained
from a patient who recently traveled to Singapore clustered with a
group of isolates from Saudi Arabia, Oman, and Kuwait (cluster
B) (Table 3). However, isolates from patients who recently trav-
eled to India and Thailand did not show similarity to any another
isolate tested (singletons 2 and 6, respectively) (Table 3). The re-
maining 46 patients did not receive overseas medical treatment.
DISCUSSION
We described the molecular genetics of CRAB isolates from pa-
tients in selected GCC hospitals. We found that OXA-23-type was
the major carbapenemase mechanism responsible for the resis-
tance phenotype. This finding is similar to data previously re-
ported from the Gulf region (3, 25, 26) and neighboring Egypt
(27). OXA-23-type contributes to carbapenem resistance in A.
TABLE 4 Demographic and clinical characteristics of 100 patients with
carbapenem-resistant A. baumannii
Characteristic No. of patients
Age (yr)
0–7 4
7–18 5
18–30 23
30–50 19
50–60 11
60–70 13
70 25
Gender
Male 68
Female 32
Residency status
Locala 79
Resident 20
No data 1
Source
Blood 18
Sputum 22
Swab 39
Urine 6
Otherb 15
Initial medical condition
Burns 6
Community acquired pneumonia 5
Hospital acquired pneumonia 8
Motor vehicle accident 17
Hemodialysis 3
Other 30
No data 31
Infection category
Health care-associated infection 24
Hospital acquired
Infection 53
Colonization 7
Community-acquired infection 8
No data 8
Antibiotic exposure before isolation
Yes 87
1–2 days 34
3–4 days 31
5–6 days 9
7 days 3
No data 10
No 12
No data 1
Previous medical history
Outpatient clinic or emergency room
30 days 14
1–6 mo 24
6–12 mo 18
12 mo 21
Hemodialysis
30 days 14
1–6 mo 9
TABLE 4 (Continued)
Characteristic No. of patients
6–12 mo 4
12 mo 5
Surgical procedure
30 days 24
1–6 mo 18
6–12 mo 5
12 mo 14
Hospital admission
30 days 46
1–6 mo 39
6–12 mo 13
12 mo 23
Recent overseas medical treatment
Yes 4
Bangladesh 1
India 1
Singapore 1
Thailand 1
No 45
Never 1
No data 50
a Citizens of the designated state.
b Includes respiratory specimens and body fluids.
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baumannii in many other parts of the world (2) and has been
associated with outbreaks in Spain (28), Italy (29), and the United
States (30). It is important to note that outbreaks have occurred as
a result of the international transfer of patients (31). This repre-
sents a risk factor to hospitals in countries where CRAB is not
endemic that receive patients from countries with a high preva-
lence of CRAB.
Epidemiological tools are important in developing effective
strategies for monitoring CRAB. We utilized rep-PCR typing us-
ing the DiversiLab system and MLST typing, as these methods
demonstrated validity in comparing geographically diverse
groups of clinical isolates (32). In this study, we found a correla-
tion between the carbapenemase gene profile and rep-PCR typing
together with MLST results. We also found that several large clus-
ters of indistinguishable isolates that produce dominant OXA-23-
type enzymes are not only circulating within hospitals of the GCC
states but also across borders. This includes the internationally
disseminated ST208 and ST195, which belong to clonal complex
92 (33–36). This finding suggests that certain strains of CRAB
have been prevalent in some Gulf region hospitals for an extended
period. It also points to the need for optimizing infection control
practices to avoid cross transmission and potential outbreaks.
Lastly, this finding highlights the unanswered question regarding
the source of A. baumannii and how certain strains found their
way into the hospital environment.
We detected OXA-40-type–producing CRAB in five isolates in
only a single hospital in Bahrain. Three of the isolates were indis-
tinguishable, but two were quite diverse (Table 3). OXA-40 pro-
ducers have been identified in Europe and the United States (2).
However, to our knowledge, this is the second report of
OXA-40 in Bahrain and the third from the GCC region (3).
Three isolates from Saudi Arabia had an ISAba1 element up-
stream of blaOXA-51-type. This carbapenem resistance mecha-
nism has been described in Saudi Arabia (37, 38). These find-
ings of sporadic resistance mechanisms might indicate a slow
change in the molecular epidemiology of CRAB in the Gulf
region.
No isolate was found to produce OXA-58, NDM, VIM, IMP, or
KPC. This is in agreement with previous work reported on CRAB
in the Gulf region (3). However, genes of the NDM type carried by
CRAB have been reported from the Indian subcontinent (39, 40),
Asia (41), Lebanon (42), and Europe (5). A related outbreak with
five cases was reported from France in an intensive care unit (ICU)
where the index patient was transferred from Algeria (43). It is
believed that NDM-1 occurred in Acinetobacter spp. before be-
coming prevalent among Enterobacteriaceae (39). Other metallo-
-lactamases, such as VIM and IMP, are less common in A. bau-
mannii (2), although recent reports from India found VIM in 45%
of tested CRAB isolates (44). KPC-producing A. baumannii were
not known (2) until a report from Puerto Rico (45), and they were
subsequently found in 4.3% of tested isolates from Puerto Rico
(46). We did not search for blaGES, although a recent report doc-
umented this -lactamase in the Gulf region (26).
In this study, we found that the vast majority (84%) of tested
CRAB isolates were associated with health care exposure. CRAB
has been described in 23% of patients with ventilator-associated
pneumonia in Riyadh (1, 47). An epidemiological study from Ri-
yadh looked at the factors related to health care-associated infec-
tions caused by multidrug-resistant A. baumannii among a pedi-
atric population and found that ICU and hospital admissions after
burns increased the risk of acquiring related infections (48). A
recent study identified patients at risk for bloodstream infection
due to A. baumannii-A. calcoaceticus complex and mainly found
that critically ill and interhospital transferred patients and patients
who were heavily exposed to health care settings and invasive de-
vices are at the highest risk (49).
In summary, we evaluated CRAB in hospitals from across Gulf
Cooperation Council states. Although this is not a formal surveil-
lance study, it is the first snapshot study to determine the molec-
ular epidemiology of CRAB in the region. Investigating the epi-
demic situation within or across hospitals provides data to
support policy making and practices in regard to infection con-
trol. Our findings of multiple large clusters of OXA-23-type–pro-
ducing A. baumannii within a hospital and across countries have
important implications in controlling the spread of CRAB in the
Middle East and in hospitals receiving patients transferred from
the region. Additionally, optimization of antibiotic stewardship in
hospitals and community pharmacies and within the agricultural
setting should be a priority for health agencies in the Gulf region.
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